Department of Oral & Maxillofacial Surgery, NÄL Medical Centre Hospital, Trollhättan, Sweden.
Clin Implant Dent Relat Res. 2013 Apr;15(2):303-8. doi: 10.1111/j.1708-8208.2011.00356.x. Epub 2011 May 9.
NEOSS® (Neoss Ltd., Harrogate, UK) dental implant system was introduced on the clinical arena in 2003. It is important that novel implant systems are systematically evaluated in a multicenter setting.
The aim of this study was to follow a large number of consecutively treated patients, with NEOSS dental implant system, both clinically and radiographically. The current report constitutes the 1-year data of a planned 5-year study.
The study included a total of 177 patients treated with 590 NEOSS implants at 13 clinics in Sweden. The material was composed of 72 males and 105 females treated for single, partial, and total edentulism. Clinical, radiographic, and subjective evaluations were performed.
Out of 590 implants, 13 early failures have been reported, corresponding to a 1-year cumulative survival rate (CSR) of 97.8%. Evaluation of function and esthetics at the 1-year visit resulted in 100% success for function and 98% success for the esthetic outcome. The mean marginal bone loss was 0.6 mm (SD 1.1) after 1 year in clinical function. No adverse effects of the NEOSS dental implants were reported, and complications were few and similar to those reported for implant treatment in general.
The CSR in the present study was 97.8%. No adverse effects of the NEOSS implants were reported, and complications during the study period were few and similar to those reported to for other well-documented implants system. Based on the present data, we conclude that NEOSS dental implant is a safe and predictable implant system. However, the high number of dropouts in the radiological evaluation must be considered when interpreting the data.
NEOSS®（英国哈罗盖特的 Neoss 有限公司）牙科种植系统于 2003 年引入临床领域。重要的是，新型种植系统需要在多中心环境中进行系统评估。
本研究旨在通过临床和影像学检查，对大量连续接受 NEOSS 牙科种植系统治疗的患者进行随访。本报告是一项为期 5 年研究的 1 年数据。
本研究共纳入 177 名患者，在瑞典的 13 家诊所接受了 590 个 NEOSS 种植体治疗。该材料由 72 名男性和 105 名女性组成，用于治疗单颗、部分和全口缺牙。进行了临床、影像学和主观评估。
在 590 个种植体中，报告了 13 个早期失败，1 年累积生存率（CSR）为 97.8%。在 1 年随访时对功能和美观进行评估，功能成功率为 100%，美观成功率为 98%。1 年后临床功能的平均边缘骨丢失为 0.6 毫米（SD 1.1）。未报告 NEOSS 牙科种植体的不良反应，并发症较少，与一般报道的种植体治疗相似。
本研究的 CSR 为 97.8%。未报告 NEOSS 种植体的不良反应，研究期间的并发症较少，与其他记录良好的种植体系统报告的并发症相似。根据目前的数据，我们得出结论，NEOSS 牙科种植体是一种安全且可预测的种植体系统。然而，在解释数据时必须考虑到影像学评估中较高的失访率。
